Development Drug Pipeline
In the course of developing our platform, we necessarily selected a target therapeutic area. Our initial datasets were built in the area of psychiatric drugs targeting relief for symptoms of schizophrenia, depression, and bipolar disorder. In the first iteration of the platform, we developed over 15,000 novel molecules and processed them through our in-silico pipeline arriving at ~60 Q-MAP™ Optimized Leads for an atypical antipsychotic with reduced risk and tolerability issues. As we continue development on the platform, a second iteration will build confidence in the designed molecules we intend to carry forward into preclinical testing.